Angioedema in the ED: Airway, Meds, Disposition | Hippo Education

When Epi Doesn't Cut It: A Practical Guide to Angioedema in the ED

You're in the middle of a busy shift when a patient walks in with a swollen lip. No big deal, right? Benadryl, maybe some steroids, send them on their way. But then another patient rolls through triage — this one has a swollen tongue, muffled voice, and she's been on lisinopril for years. You give the usual anaphylaxis cocktail, and... nothing. The swelling isn't budging.

Welcome to the world of angioedema, where not all swelling is created equal, and where the treatment that works great for one type does almost nothing for another.

In a recent ERcast episode, I sat down with Dr. Brit Long to break down the evaluation, airway management, and medication options for angioedema. Here are the highlights you need to know.

It's Not All Histamine

The most important shift in managing angioedema is understanding that there are two fundamentally different pathways: histamine-mediated and bradykinin-mediated. This distinction matters because your go-to treatment for one type is essentially useless for the other.

Histamine-mediated angioedema is what most of us think of when we hear "angioedema." It's often associated with allergic reactions, comes on within minutes, and typically presents with urticaria, pruritus, and symmetric swelling of the lips and eyes. The good news: Epinephrine, antihistamines, and steroids work well. Around 90% of these patients will respond to your standard anaphylaxis protocol.

Bradykinin-mediated angioedema is a different animal entirely. It includes hereditary angioedema (HAE) and, more commonly in the ED, ACE inhibitor-induced angioedema. The onset is slower (hours, not minutes), it tends to be asymmetric and tongue-dominant, and you typically won't see urticaria. Most importantly, epinephrine, antihistamines, and steroids have less than a 10% response rate.

Here's a quick comparison to help you sort them out at the bedside:

So if you've given your standard cocktail and the patient isn't improving, you're probably dealing with bradykinin and you need a different game plan.

The Airway: Your First (and Maybe Only) Priority

Let's be clear: asphyxiation is the number one cause of death in acute angioedema. Up to 15% of patients experience airway obstruction, and it can progress rapidly. For patients with hereditary angioedema, over 50% will experience laryngeal edema at some point in their lifetime, and it accounts for more than 30% of HAE deaths.

Red flags for airway involvement:

• Lip and tongue swelling (especially anterior tongue)
• Voice changes, hoarseness, stridor
• Drooling
• Difficulty swallowing
• Dyspnea or inability to lie flat

One reassuring finding: isolated lip swelling is generally low-risk for airway intervention. But once you see tongue involvement, soft palate edema, or any voice changes, your concern should escalate quickly.

If you decide to intubate, here's the approach:

1. Don't wait for medications to work. Angioedema-specific treatments take time (sometimes over an hour), and your patient's airway won't wait.
2. If you have 15-20 minutes: Awake intubation with flexible intubating endoscopy is ideal.
3. If not feasible: Video laryngoscopy, but go gently — excessive manipulation can worsen edema.
4. Always prepare for a surgical airway. This is crucial: up to 50% of angioedema patients requiring emergent airway intervention end up needing cricothyrotomy or tracheostomy.

Use a double setup. Have your surgical airway ready before you start.

The Medication Rundown

For unknown etiology or histamine-mediated angioedema:

Your standard approach works: epinephrine, antihistamines, corticosteroids. Even if you're not sure what type you're dealing with, it's reasonable to start here — these medications haven't been shown to cause harm in bradykinin-mediated cases, they just won't help much.

For bradykinin-mediated angioedema (HAE, ACE inhibitor-induced):

This is where things get more complicated. The first-line treatments are C1 esterase inhibitor (C1-INH) replacements:

• Berinert® or Cinryze® (plasma-derived C1-INH): IV, onset <50 minutes
• Ruconest® (recombinant C1-INH): IV, onset ~90 minutes
• Ecallantide (Kalbitor®): Kallikrein inhibitor, SubQ, onset ~67 minutes
• Icatibant (Firazyr®): Bradykinin B2 receptor antagonist, SubQ, onset ~2 hours

Many EDs don't stock these medications, and even when they do, the onset times mean you can't rely on them for acute airway compromise. Treatment within 6 hours of symptom onset improves outcomes, so if you have access to these medications, use them early.

What If You Don't Have the Fancy Stuff?

Tranexamic acid (TXA) is worth considering. The mechanism makes sense — it inhibits plasmin, which is involved in bradykinin generation. Retrospective studies suggest benefit with no severe adverse events, and the advantages are hard to argue with: it's cheap, it's safe, and every ED has it. Dose is 1 g IV over 2-10 minutes, and you can repeat if needed.

What about FFP? Fresh frozen plasma contains both ACE (which degrades bradykinin) and C1-INH, so the logic seems sound. The problem is that FFP also contains substrates of the kallikrein system that may actually worsen angioedema. The evidence is limited and the potential for harm is real. Avoid it if you have other options.

Disposition: Who Goes Home?

The Ishoo staging system is helpful here:

Stage 1 patients can often be observed for several hours and discharged with close follow-up. Stage 2 or higher should be admitted. Any patient with airway involvement goes to the ICU. Any patient who worsens despite treatment gets admitted.

The limitation of this staging system is that it requires direct visualization of laryngeal structures, so if you're worried, scope them.

Before They Leave: The Discharge Checklist

For patients appropriate for discharge:

• Stop the offending medication. If they're on an ACE inhibitor, discontinue it and list it as an allergy. ARBs are generally safe to switch to — the angioedema incidence is around 0.11%, similar to placebo.
• Refer to allergy/immunology for recurrent angioedema. They can identify triggers, diagnose underlying causes, and prescribe prophylactic medications.
• Prescribe an epinephrine autoinjector if the patient responded to anaphylaxis treatment.
• Educate on warning signs and when to return.

One Disease, Two Pathways

Angioedema isn't one disease; it's at least two different pathways that look similar but need completely different treatments. The next time you have a patient who's not responding to your usual anaphylaxis protocol, you'll know why. And more importantly, you'll know what to reach for instead.

Key takeaways:

1. Airway first, always. Up to 50% of intubated angioedema patients need a surgical airway.
2. Know the difference. Slow onset + tongue involvement + no urticaria + not responding to epi = think bradykinin.
3. Epi/antihistamines/steroids work for histamine-mediated (~90%). They don't work for bradykinin (<10%).
4. C1-INH replacement is first-line for bradykinin-mediated angioedema if available.
5. TXA is a reasonable option when you don't have access to specific therapies.
6. Stop the ACE inhibitor and list it as an allergy.
   
   

You can hear more on this topic on the ERcast segment, "Swollen Airways & Sickled Cells."